去甲氧柔红霉素治疗急性白血病的疗效评价

Evaluation on the Efficacy of Idarubicin in the Treatment of Acute Leukemia

目的探究去甲氧柔红霉素治疗急性白血病的临床疗效。方法本次研究选取于2013年10月—2016年11月来我院就医的急性白血病患者(80例),通过患者自身经济能力进行分组,即经济能力较好的患者为观察组,经济能力较差的患者为对照组,分别给予去甲氧柔红霉素、柔红霉素治疗,探究两组患者近期疗效以及不良反应发生率的差异性。结果观察组患者的近期疗效(完全缓解:50.00%)与对照组患者比较,差异有统计学意义,P<0.05,而在不良反应发生率的比较中,观察组为77.50%(31/40),对照组为70.00%(28/40),P>0.05,差异不具有统计学意义。同时,观察组患者的毒副作用与对照组患者的结果相对比,差异有统计学意义(P<0.05)。结论去甲氧柔红霉素治疗急性白血病具有一定效果,可提高近期疗效。

Objective To explore the clinical efficacy of idarubicin in the treatment of acute leukemia. Methods In this study, selected 80 patients with acute leukemia who were admitted to our hospital from October 2013 to November 2016. They were divided into two groups according to their own economic ability, the economic ability of the patients was better in the observation group. Poor patients as the control group. They were given daunorubicin or idarubicin for treatment, to explore the two groups of patients with short-term efficacy and the incidence of adverse reactions differences. Results The short-term efficacy of the observation group （complete remission： 50.00%） compared with the control group, the difference was statistically significant（P 〈 0.05）. And in the incidence of adverse reactions in the observation group was 77.50% （31/40）, the control group was 70.00% （28/40）, P 〉 0.05, the difference was not statistically significant. At the same time, the side effects of the observation group were compared with those of the control group, the difference was statistically significant （P 〈 0.05）. Conclusion Idarubicin for acute leukemia has a certain effect, can improve the short-term effect.